Disc Net Income From Continuing Ops from 2010 to 2026
| IRON Stock | 79.71 0.94 1.17% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -98.4 M | Current Value -103.3 M | Quarterly Volatility 24.8 M |
Check Disc Medicine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Disc Medicine's main balance sheet or income statement drivers, such as Net Interest Income of 25 M, Interest Income of 25.7 M or Depreciation And Amortization of 111.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.73. Disc financial statements analysis is a perfect complement when working with Disc Medicine Valuation or Volatility modules.
Disc | Net Income From Continuing Ops | Build AI portfolio with Disc Stock |
Evaluating Disc Medicine's Net Income From Continuing Ops across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Disc Medicine's fundamental strength.
Latest Disc Medicine's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Disc Medicine over the last few years. It is Disc Medicine's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Disc Medicine's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Disc Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (55,477,510) | |
| Coefficient Of Variation | (44.64) | |
| Mean Deviation | 19,964,249 | |
| Median | (40,837,000) | |
| Standard Deviation | 24,766,105 | |
| Sample Variance | 613.4T | |
| Range | 68.5M | |
| R-Value | (0.77) | |
| Mean Square Error | 262.9T | |
| R-Squared | 0.60 | |
| Significance | 0.0003 | |
| Slope | (3,793,123) | |
| Total Sum of Squares | 9813.8T |
Disc Net Income From Continuing Ops History
About Disc Medicine Financial Statements
Disc Medicine investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Disc Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -98.4 M | -103.3 M |
Pair Trading with Disc Medicine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Disc Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Disc Medicine will appreciate offsetting losses from the drop in the long position's value.Moving together with Disc Stock
Moving against Disc Stock
| 0.75 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.63 | 63E | ONWARD MEDICAL BV | PairCorr |
| 0.54 | ENGN | enGene Holdings Common | PairCorr |
| 0.47 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.32 | DSGN | Design Therapeutics | PairCorr |
The ability to find closely correlated positions to Disc Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Disc Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Disc Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Disc Medicine to buy it.
The correlation of Disc Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Disc Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Disc Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Disc Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Disc Medicine Correlation against competitors. To learn how to invest in Disc Stock, please use our How to Invest in Disc Medicine guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Biotechnology sector continue expanding? Could Disc diversify its offerings? Factors like these will boost the valuation of Disc Medicine. Market participants price Disc higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Disc Medicine data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Disc Medicine using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Disc Medicine's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Disc Medicine's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Disc Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Disc Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Disc Medicine's market price signifies the transaction level at which participants voluntarily complete trades.